Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study.

IMI/REL KDIGO criteria RIFLE criteria acute kidney injury colistin

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 21 11 2019
accepted: 18 02 2020
entrez: 11 3 2020
pubmed: 11 3 2020
medline: 11 3 2020
Statut: epublish

Résumé

In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effective as colistin plus IMI for the treatment of imipenem-nonsusceptible gram-negative infections. Differences in nephrotoxicity were observed between treatment arms. As there is no standard definition of nephrotoxicity used in clinical trials, we conducted analyses to further understand the renal safety profile of both treatments. Nephrotoxicity was retrospectively evaluated using 2 acute kidney injury assessment criteria (Kidney Disease Improving Global Outcomes [KDIGO] and Risk, Injury, Failure, Loss, and End-stage Kidney Disease [RIFLE]). Additional outcomes included time to onset of protocol-defined nephrotoxicity and incidence of renal adverse events. Of 47 participants receiving treatment, 45 had sufficient data to assess nephrotoxicity (IMI/REL, n = 29; colistin plus IMI, n = 16). By KDIGO criteria, no participants in the IMI/REL but 31.3% in the colistin plus IMI group experienced stage 3 acute kidney injury. No IMI/REL-treated participants experienced renal failure by RIFLE criteria, vs 25.0% for colistin plus IMI. Overall, the time to onset of nephrotoxicity varied considerably (2-22 days). Fewer renal adverse events (12.9% vs 37.5%), including discontinuations due to drug-related renal adverse events (0% vs 12.5%), were observed in the IMI/REL group compared with the colistin plus IMI group, respectively. Our analyses confirm the findings of a preplanned end point and provide further evidence that IMI/REL had a more favorable renal safety profile than colistin-based therapy in patients with serious, imipenem-nonsusceptible gram-negative bacterial infections. NCT02452047.

Sections du résumé

BACKGROUND BACKGROUND
In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effective as colistin plus IMI for the treatment of imipenem-nonsusceptible gram-negative infections. Differences in nephrotoxicity were observed between treatment arms. As there is no standard definition of nephrotoxicity used in clinical trials, we conducted analyses to further understand the renal safety profile of both treatments.
METHODS METHODS
Nephrotoxicity was retrospectively evaluated using 2 acute kidney injury assessment criteria (Kidney Disease Improving Global Outcomes [KDIGO] and Risk, Injury, Failure, Loss, and End-stage Kidney Disease [RIFLE]). Additional outcomes included time to onset of protocol-defined nephrotoxicity and incidence of renal adverse events.
RESULTS RESULTS
Of 47 participants receiving treatment, 45 had sufficient data to assess nephrotoxicity (IMI/REL, n = 29; colistin plus IMI, n = 16). By KDIGO criteria, no participants in the IMI/REL but 31.3% in the colistin plus IMI group experienced stage 3 acute kidney injury. No IMI/REL-treated participants experienced renal failure by RIFLE criteria, vs 25.0% for colistin plus IMI. Overall, the time to onset of nephrotoxicity varied considerably (2-22 days). Fewer renal adverse events (12.9% vs 37.5%), including discontinuations due to drug-related renal adverse events (0% vs 12.5%), were observed in the IMI/REL group compared with the colistin plus IMI group, respectively.
CONCLUSIONS CONCLUSIONS
Our analyses confirm the findings of a preplanned end point and provide further evidence that IMI/REL had a more favorable renal safety profile than colistin-based therapy in patients with serious, imipenem-nonsusceptible gram-negative bacterial infections.
CLINICALTRIALSGOV IDENTIFIER BACKGROUND
NCT02452047.

Identifiants

pubmed: 32154325
doi: 10.1093/ofid/ofaa054
pii: ofaa054
pmc: PMC7052751
doi:

Banques de données

ClinicalTrials.gov
['NCT02452047']

Types de publication

Journal Article

Langues

eng

Pagination

ofaa054

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Lancet Infect Dis. 2013 Sep;13(9):785-96
pubmed: 23969216
Clin Infect Dis. 2015 Dec 15;61(12):1771-7
pubmed: 26354965
N Engl J Med. 2019 Feb 21;380(8):791-793
pubmed: 30786196
Ann Clin Microbiol Antimicrob. 2015 Jan 16;14:3
pubmed: 25591721
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27895014
Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176
pubmed: 29026867
Pharmacotherapy. 2019 Jan;39(1):10-39
pubmed: 30710469
Clin Infect Dis. 2016 Dec 15;63(12):1605-1612
pubmed: 27794023
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038261
Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):15
pubmed: 29571295
Antimicrob Agents Chemother. 2014 May;58(5):2740-6
pubmed: 24566187
Clin Infect Dis. 2019 Aug 10;:
pubmed: 31400759
J Formos Med Assoc. 2017 Nov;116(11):844-851
pubmed: 28874330
Clin Infect Dis. 2011 Nov;53(9):879-84
pubmed: 21900484
AAPS J. 2011 Dec;13(4):615-31
pubmed: 21969220
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
Dtsch Arztebl Int. 2018 May 21;115(20-21):345-352
pubmed: 29914612
J Antimicrob Chemother. 2010 Oct;65(10):2231-7
pubmed: 20685752
Clin Infect Dis. 2013 Aug;57(3):349-58
pubmed: 23616495
Rev Bras Ter Intensiva. 2013 Oct-Dec;25(4):290-6
pubmed: 24553510
BMC Infect Dis. 2017 Apr 17;17(1):279
pubmed: 28415969
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29844039
J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2-iii78
pubmed: 29514274
Clin Infect Dis. 2013 Nov;57(9):1300-3
pubmed: 23840000
Crit Care. 2014 Jul 08;18(4):R144
pubmed: 25005361
J Glob Antimicrob Resist. 2018 Dec;15:127-135
pubmed: 30010061
Infect Dis Ther. 2018 Dec;7(4):439-455
pubmed: 30270406
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559250
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
Clin Infect Dis. 2016 Mar 1;62(5):552-558
pubmed: 26607424
Am J Infect Control. 2016 Nov 1;44(11):1275-1279
pubmed: 27320901

Auteurs

Michelle L Brown (ML)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Johann Motsch (J)

Universitätsklinikum Heidelberg, Heidelberg, Germany.

Keith S Kaye (KS)

University of Michigan, Ann Arbor, Michigan, USA.

Thomas M File (TM)

Summa Health, Akron, Ohio, USA.

Helen W Boucher (HW)

Tufts Medical Center, Boston, Massachusetts, USA.

Neika Vendetti (N)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Angela Aggrey (A)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Hee-Koung Joeng (HK)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Robert W Tipping (RW)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Jiejun Du (J)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Daryl D DePestel (DD)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Joan R Butterton (JR)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Amanda Paschke (A)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Classifications MeSH